Several targeting approaches are in development. BCMA is preferentially expressed on plasma cells and other mature B cells in blood 5. These cells originate with B-lymphocyte progenitors that ...

It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK's first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio's ...

A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

Blenrep (belantamab mafodotin) becomes the first BCMA-targeted drug for myeloma to be approved in the EU, and according to its label can be used to treat the blood cancer in adult patients who ...